PUNE, India, November 20, 2015 /PRNewswire/ --
Global Nateglinide Industry 2015 Market Research Report is a comprehensive business study on the current state of the Nateglinide providing competitive analysis in form of 5 company profiles along with their product picture and specification, capacity production price cost production value and contact information.
Complete report on Nateglinide market spread across 155 pages providing 5 company profiles and 150 tables and figures is available at http://www.rnrmarketresearch.com/global-nateglinide-industry-2015-market-research-report-market-report.html .
The report provides a basic overview of Nateglinide market including definitions, classifications, applications and industry chain structure. The analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans of Nateglinide market are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand figures, cost price and production value gross margins.
The report focuses on global major nateglinide market players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Nateglinide market development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.
With 150 tables and figures to support nateglinide market analysis, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. 5 Companies profiled in this report include Novartis, Deyuan Pharm, Luoxin Pharmacy Group, Chia Tai Tianqing Pharmaceutical Group and Nanjing Hailing Pharmaceutical. Order a copy of Global Nateglinide Industry 2015 Market Research Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=434167 .
Forecasts provided in this Nateglinide market report include 2016-2021 Nateglinide capacity production overview, production market share, consumption overview, supply consumption and shortage, import export consumption as well as cost price production value gross margin. Few tables and figures provided in this research include
Explore more reports on the Pharmaceuticals market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .
Other research titled Investigation Report on China Nateglinide Market, 2010-2019 says according to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). According to CRI's market survey, Beijing Novartis Pharma Ltd. took up a market share of about 95% for sales value in 2014 while other companies like Deyuan Pharm, Luoxin Pharmacy Group Co., Ltd and Chia Tai Tianqing Pharmaceutical Group Co., Ltd together occupied about 5% of the nateglinide market in China. The sales value of nateglinide was CNY 67 million in 2014 and CAGR during the period of 20052014 reached about 40%.
Developed by the Japanese company Ajinomoto, anateglinide is the new oral nonsulfonylurea drug for the treatment of type 2 diabetes mellitus (T2DM). First appearing in the Japanese market in 1999, anateglinide was marketed by Novartis in the US in 2001 and later entered China in 2003. Currently, anateglinide in the Chinese market mainly comes from Beijing Novartis (Trade Name: Starlix), Deyuan Pharm, Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Bei Jia) and Nanjing Hailing Pharmaceutical Co., Ltd (Trade Name: Qifu).
The market size of nateglinide is expected to keep growing in the next few years in China. Complete Report is available at http://www.rnrmarketresearch.com/investigation-report-on-china-nateglinide-market-2010-2019-market-report.html .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
SOURCE RnR Market Research